Sexual Reassignment Fails to Prevent Kennedy's Disease.

Spinal and bulbar muscular atrophy is caused by polyglutamine expansion in the androgen receptor. As an X-linked disease dependent on androgens, symptoms and findings are only fully manifest in males. Here we describe a 40-year-old male-to-female transgender SBMA patient who developed full disease manifestations despite undetectable levels of androgens. We used cell culture and animal models to show that spironolactone, the anti-androgen she had taken for 15 years, promotes nuclear localization and toxicity of the mutant protein, which may explain the disease manifestations in this patient.

[1]  J. Andreasen,et al.  Work Status and Return to the Workforce after Coronary Artery Bypass Grafting and/or Heart Valve Surgery: A One-Year-Follow Up Study , 2014, Rehabilitation research and practice.

[2]  K. Fischbeck,et al.  Assessing Function and Endurance in Adults with Spinal and Bulbar Muscular Atrophy: Validity of the Adult Myopathy Assessment Tool , 2014, Rehabilitation research and practice.

[3]  S. Sundar,et al.  Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate , 2012, BMJ Case Reports.

[4]  Rebecca B. Smith,et al.  Native Functions of the Androgen Receptor Are Essential to Pathogenesis in a Drosophila Model of Spinobulbar Muscular Atrophy , 2010, Neuron.

[5]  K. Fischbeck,et al.  Clinical features of spinal and bulbar muscular atrophy , 2009, Brain : a journal of neurology.

[6]  G. Sobue,et al.  Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy , 2002, Neuron.

[7]  F. Orio,et al.  A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects , 2000, Molecular and Cellular Endocrinology.

[8]  M. Rogers,et al.  Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites , 1989, Journal of clinical pharmacology.

[9]  J. Ménard,et al.  Antiandrogenic effect of spirolactones: mechanism of action. , 1975, Endocrinology.

[10]  K. Fischbeck,et al.  Spinal and bulbar muscular atrophy: pathogenesis and clinical management. , 2014, Oral diseases.

[11]  A. Karim,et al.  Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. , 1978, Drug metabolism reviews.